Evidence map›Paper›PMID 25852975›Full record

ReviewInnovations in clinical neuroscience

Lurasidone: a new treatment option for bipolar depression-a review.

Radhika Bawa, Jonathan R Scarff

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in Innovations in clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Lurasidone-induced Oculogyric Crisis.Indian journal of psychological medicine
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Radhika BawaDr. Bawa is with Lehman College, the City University of New York, Bronx, New York; and Dr. Scarff is with Veterans Affairs Outpatient Clinic, Spartanburg, South Carolina.
Jonathan R ScarffDr. Bawa is with Lehman College, the City University of New York, Bronx, New York; and Dr. Scarff is with Veterans Affairs Outpatient Clinic, Spartanburg, South Carolina.
American University of Beirut Medical Center · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depressive episodes in bipolar disorder contribute to significant morbidity and mortality. Until recently, only quetiapine and an olanzapine-fluoxetine combination were approved to treat bipolar depression. Recently, lurasidone was approved to treat bipolar depression either as monotherapy or adjunctively with lithium or valproate. Lurasidone was well- tolerated, and commonly observed adverse reactions (incidence ≥5% and at least twice the rate for placebo) were akathisia, extrapyramidal symptoms, and somnolence. There were no significant metabolic or electrocardiogram abnormalities. It is taken with food to ensure maximal absorption, and dose should be adjusted in patients who receive moderate CYP450 inhibitors or inducers and in patients with renal disease.

Indexed as

antipsychoticBipolar disorderdepressionlurasidone

Identifiers

PMID25852975
PMCPMC4382136
OpenAlexW255597822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.